Some medical tech startups are trying to “disrupt” respiratory care. ABM Respiratory Care? They’re actually breathing new life into it.
Founded in 2017 out of Singapore by CTO Vinay Joshi and Co-Founder Chad Boerst, ABM started with a pretty wild premise for medtech: what if airway clearance didn’t have to be outdated, invasive, or siloed? What if lung therapy could actually work better, faster, and dare we say, smarter?
Fast forward to 2025, and they’ve locked in $14.8M in an oversubscribed Series B round led by healthcare stalwart Peter H. Soderberg, Chairman of the Board and Managing Partner at Worthy Venture Resources LLC. Blue Wave Capital came in heavy, too, with Co-Founder Jonathan Black now on the board, joining a return cast that includes Advanced MedTech Holdings and SEEDS Capital. This brings total funding to $25.1M. No valuations were disclosed, but let’s just say this round wasn’t built on hope and dreams, it was built on traction and tech.
Under CEO Gregory Miller, who stepped in mid-2024 after steering Advanced MedTech’s financial strategy and clocking time as EVP/CIO at Genuine Parts Company, ABM’s U.S. operations have scaled fast. From a lean 12-person crew in 2020 to a 74-strong team spanning clinical affairs, sales, and R&D across Eagan, Minnesota to Charlotte, Dallas, and Singapore, they’re not just growing, they’re targeting with precision.
Their flagship BiWaze® Clear system is a three-tool beast: lung expansion, high-frequency oscillation, and aerosol delivery, wrapped in one portable, telehealth-enabled device. It doesn’t just play nice with ventilators, it rewrites outcomes: 64% less ventilator time and 47% fewer pulmonary complications, per real-world deployments in over 50 U.S. hospitals and 200+ home care programs.
And they’re not stopping. The Alpha Ventilator is pushing into the invasive/non-invasive zone with remote therapy management. They’ve got PMA filings coming, a direct-to-consumer play brewing, and eyes on EU/APAC expansion by late 2025. FDA 510(k) clearances? Already secured. ISO13485? Check. Dual-blower IP and a disposable dual-lumen circuit? Patent pending, but game-changing.
Vinay Joshi brings two decades of deep med device wisdom from GE Healthcare and Hill-Rom, backed by degrees from IIT Delhi and IIM Bangalore. Chad Boerst engineered his way through GN Otometrics and Hill-Rom with a mechanical edge and an MBA from Charleston Southern. The leadership bench? Stacked. Leah Noaeill’s clinical marketing chops, Amodh Gr’s systems-first R&D brain, and Sean Mellor driving U.S. sales like he’s got oxygen on tap.
The world’s 25 million+ COPD and cystic fibrosis patients aren’t waiting around, and neither is ABM. The global airway clearance market is projected to nearly double by 2035. ABM isn’t chasing that curve, they’re bending it.
This isn’t just medtech. It’s a masterclass in how focus, timing, and deep sector knowledge get capital to follow capability. ABM didn’t raise $14.8M to find product-market fit. They raised it to scale something that’s already working.
And if you’re in respiratory therapy, hospital systems, or home-care delivery and still haven’t looked at BiWaze®, you might be the one who’s short of breath.
